cyclohexylaminoglutethimide has been researched along with aclarubicin in 1 studies
| Studies (cyclohexylaminoglutethimide) | Trials (cyclohexylaminoglutethimide) | Recent Studies (post-2010) (cyclohexylaminoglutethimide) | Studies (aclarubicin) | Trials (aclarubicin) | Recent Studies (post-2010) (aclarubicin) |
|---|---|---|---|---|---|
| 8 | 0 | 2 | 826 | 97 | 105 |
| Protein | Taxonomy | cyclohexylaminoglutethimide (IC50) | aclarubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 9.9 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.106 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Wei, XD; Yin, QS | 1 |
1 other study(ies) available for cyclohexylaminoglutethimide and aclarubicin
| Article | Year |
|---|---|
[Comparative evaluation of CHAG and CAG priming regimen for treatment of refractory and relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Glutethimide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |